Procaterol HCl Hemihydrate
CAS : 81262-93-3
Ref. 3D-FP146992
| 1g | Arrêté | ||
| 50mg | Arrêté | ||
| 100mg | Arrêté | ||
| 250mg | Arrêté | ||
| 500mg | Arrêté |
Informations sur le produit
- (R*,S*)-(-)-8-Hydroxy-5-(1-hydroxy-2-((1-methylethyl)amino)butyl)-2(1H)-quinolinone hydrochloride
- 8-hydroxy-5-[1-hydroxy-2-(propan-2-ylamino)butyl]quinolin-2(1H)-one
- 8-hydroxy-5-[(1R,2S)-1-hydroxy-2-(propan-2-ylamino)butyl]quinolin-2(1H)-one hydrochloride (1:1)
- 8-hydroxy-5-[1-hydroxy-2-(propan-2-ylamino)butyl]quinolin-2(1H)-one hydrochloride (1:1)
- 8-hydroxy-5-{1-hydroxy-2-[(1-methylethyl)amino]butyl}quinolin-2(1H)-one hydrochloride hydrate
- (1R,2S)-1-hydroxy-1-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)-N-(1-methylethyl)butan-2-aminium
Procaterol is a bronchodilator that binds to the beta-2 adrenergic receptors on the smooth muscle in the bronchial tree. It stimulates these receptors, which causes bronchial dilation and an increase in airway flow. The drug has been shown to be effective for chronic cough, but not for acute cough. Procaterol is available as a rapid-acting oral formulation, as well as a slow-release form for once-daily administration. This drug has not been studied in children younger than 18 years of age. Procaterol HCl Hemihydrate is indicated for the treatment of obstructive airways disease, including chronic bronchitis and emphysema, and asthma. Procaterol is also used to treat or prevent bronchospasm in patients with reversible obstructive airways disease who are exposed to substances that can cause bronchospasm.
